Based on the analysis of Bruker's profitability, liquidity, and operating efficiency, Bruker is performing exceptionally good at this time. It has a great probability to report excellent financial results in January. At this time, Bruker's Total Liabilities is relatively stable compared to the past year. As of 12/01/2024, Short and Long Term Debt Total is likely to grow to about 1.4 B, though Other Stockholder Equity is likely to grow to (906.6 M). Key indicators impacting Bruker's financial strength include:
Investors should never underestimate Bruker's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bruker's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bruker.
Net Income
448.56 Million
Bruker
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Account Receivables
Change To Netincome
Change To Liabilities
Stock Based Compensation
Sale Purchase Of Stock
Total Cashflows From Investing Activities
Dividends Paid
Change Receivables
Net Borrowings
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Total Stockholder Equity
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Inventory
Other Current Assets
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Other Liab
Long Term Debt
Short Term Investments
Property Plant Equipment
Current Deferred Revenue
Treasury Stock
Good Will
Net Tangible Assets
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Additional Paid In Capital
Deferred Long Term Liab
Non Current Liabilities Other
Deferred Long Term Asset Charges
Short Long Term Debt
Net Invested Capital
Net Working Capital
Warrants
Capital Lease Obligations
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Total Other Income Expense Net
Depreciation And Amortization
Selling General Administrative
Research Development
Cost Of Revenue
Income Before Tax
Income Tax Expense
Net Income Applicable To Common Shares
Selling And Marketing Expenses
Minority Interest
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Bruker Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bruker's financial statements are interrelated, with each one affecting the others. For example, an increase in Bruker's assets may result in an increase in income on the income statement.
Bruker competes with Orthofix Medical, Glaukos Corp, Integer Holdings, CONMED, and LivaNova PLC. Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. Bruker Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 7765 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Bruker's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Bruker's current stock value. Our valuation model uses many indicators to compare Bruker value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bruker competition to find correlations between indicators driving Bruker's intrinsic value. More Info.
Bruker is number one stock in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.24 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bruker is roughly 4.08 . At this time, Bruker's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bruker by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Bruker Systematic Risk
Bruker's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bruker volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Bruker correlated with the market. If Beta is less than 0 Bruker generally moves in the opposite direction as compared to the market. If Bruker Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bruker is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bruker is generally in the same direction as the market. If Beta > 1 Bruker moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Bruker Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bruker's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bruker growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Bruker help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bruker. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bruker based on widely used predictive technical indicators. In general, we focus on analyzing Bruker Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bruker's daily price indicators and compare them against related drivers.
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.